Covetrus Inc (NASDAQ:CVET) has earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Brokers have set a one year consensus price objective of $42.00 for the company and are predicting that the company will post $0.17 EPS for the current quarter, according to Zacks. Zacks has also assigned Covetrus an industry rank of 39 out of 255 based on the ratings given to related companies.
CVET has been the subject of a number of research analyst reports. Credit Suisse Group initiated coverage on Covetrus in a research report on Thursday, April 4th. They issued a “neutral” rating and a $35.00 price target for the company. William Blair initiated coverage on Covetrus in a research report on Tuesday, February 12th. They issued an “outperform” rating for the company. Raymond James initiated coverage on Covetrus in a research report on Wednesday, February 27th. They issued an “outperform” rating and a $45.00 price target for the company. Zacks Investment Research cut Covetrus from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Svb Leerink restated an “outperform” rating on shares of Covetrus in a research report on Wednesday, March 20th.
Covetrus, Inc engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded on April 13, 2018 and is headquartered in Melville, NY.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.